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Objective:The aim of this systematic review andmeta-analysis was to determine the effectiveness of perioperative strategies
to prevent infection in patients undergoing peripheral arterial reconstruction.
Methods: All randomized controlled trials (RCTs) evaluating measures intended to reduce or prevent infection in arterial
surgery were identified through searches of the Cochrane Peripheral Vascular Diseases Group specialized trials register,
the Cochrane Central Register of Controlled Trials (CENTRAL), and reference lists of relevant articles. Two authors
independently selected and assessed the quality of included trials. Relative risk (RR) was used as a measure of effect for
each dichotomous outcome.
Results:The study included 34 RCTs. Of these, 22 were trials of prophylactic systemic antibiotics, 3 of rifampicin-bonded
grafts, 3 of preoperative skin antisepsis, 2 of suction wound drainage, 2 of minimally invasive in situ bypass techniques,
and individual trials of intraoperative glove change and wound closure techniques. Wound infection or early graft
infection outcomes were recorded in all trials. Only two trials, both of rifampicin bonding, followed up graft infection
outcomes to 2 years. Prophylactic systemic antibiotics reduced the risk of wound infection (RR, 0.25; 95% confidence
interval [CI], 0.17 to 0.38) and early graft infection in a fixed-effect model (RR, 0.31; 95% CI, 0.11 to 0.85, P  .02).
Antibiotic prophylaxis for >24 hours appeared to be of no added benefit (RR, 1.28; 95% CI, 0.82 to 1.98). There was
no evidence that prophylactic rifampicin bonding to Dacron grafts reduced graft infection at 1 month (RR, 0.63; 95% CI,
0.27 to 1.49), or 2 years (RR, 1.05; 95% CI, 0.46 to 2.40). There was no evidence of a beneficial or detrimental effect on
rates of wound infection with suction groin wound drainage (RR, 0.96; 95% CI, 0.50 to 1.86) or from preoperative
bathing with antiseptic agents compared with unmedicated bathing (RR, 0.97; 95% CI, 0.70 to 1.36).
Conclusions: There is clear evidence of the benefit of prophylactic broad-spectrum antibiotics for vascular reconstruction.
Many other interventions intended to reduce the risk of infection in arterial reconstruction lack evidence of effectiveness.
(J Vasc Surg 2007;46:148-55.)Infection of biologic or prosthetic peripheral arterial
grafts can lead to catastrophic outcomes ranging from loss
of limb to death. The increasing prevalence of resistant
bacteria has been associated with worsened outcomes.
Many maneuvers are used in an attempt to reduce infection
in arterial reconstructions, but there are no clear guidelines
on the most appropriate or effective. Most graft infections
are the result of the direct spread of bacteria from an
infected wound; therefore, equal consideration needs to be
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148given to the prevention and management of wound infec-
tion.
The aim of this systematic review and meta-analysis was
to evaluate the evidence for the effectiveness of interven-
tions to prevent wound and graft infection in peripheral
arterial reconstruction and to identify areas where evidence
is lacking.
METHODS
Randomized controlled trials (RCTs) evaluating any
intervention undertaken with the intention of reducing or
preventing infection in peripheral arterial surgery were
identified by searches of The Cochrane Peripheral Vascular
Diseases Group specialized register (last searched May
2006) and the Cochrane Central Register of Controlled
Trials (CENTRAL) in The Cochrane Library (last searched
Issue 2, 2006). The specialized register is constructed from
electronic searches of United States National Library of
Medicine database (MEDLINE; 1966 to date), Excerpta
Medica database (EMBASE; 1980 to date), and Cumula-
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date), and through hand-searching relevant journals. Ref-
erence lists from articles highlighted by the above search
strategies were also hand-searched.
RCTs that included patients undergoing peripheral
arterial reconstruction with biologic or prosthetic graft
were selected. Trials were excluded if they included patients
with pre-existing graft infection or infection at the pro-
posed operative site. Outcomes retrieved were wound or
graft infection established by positive microbial cultures or
clinical signs of infection. The Schulz et al1 scale was used
to assess quality of allocation concealment and the Jadad et
al2 scale to assess randomization method, blinding, and
outcome of all study participants.
Statistical analysis. The statistical guidelines for re-
view authors of the Cochrane Peripheral Vascular Diseases
Group were used to analyze the data. Relative risk (RR)
with 95% confidence intervals (CI) was used as a measure of
effect for each dichotomous outcome. Where there were
sufficient data, a summary statistic for each outcome was
calculated by using a fixed-effect model and a random-
effects model. Sensitivity analyses were undertaken to ex-
amine the stability of the results in relation to a number of
factors, including study quality, the source of the data
(published or unpublished), and patient type.
RESULTS
The search strategy identified 48 eligible reports, 35 of
which are included in this review. Amongst these were 10
studies of antibiotic prophylaxis vs placebo,3-12 3 studies of
short-duration antibiotics (24 hours) vs long-duration
antibiotics (24 hours),6,13,14 3 studies of rifampicin im-
pregnation of graft material,15-18 2 studies of suction
wound drainage,19,20 and 3 studies of preoperative skin
antisepsis,21-23 A further 10 studies compared different
prophylactic antibiotics or doses.11,24-32 One trial each of
intraoperative glove change,33 wound closure technique,34
and single dose vs antibiotics for 24 hours,35 and two trials
of a closed in situ bypass technique were also of adequate
quality for inclusion.36,37 One study was reported in two
publications,14,15 and one report12 included 2 substudies.
Infective outcomes in a subset of vascular patients
could not be differentiated from the overall study popula-
tion in one study of preoperative hair removal,38 one study
of a short vs a long course of cefamandole in vascular and
thoracic patients,39 and one study comparing cefazolin
with ceftriaxone in cardiac and vascular patients.40 These
studies were therefore excluded, as were five studies where
infective outcomes were not reported,41-45 four quasi-
randomized studies,46-49 and one study with unclear inclu-
sion criteria and equivalence of randomized groups.50
All 35 included studies were RCTs. The methodologic
quality of included studies varied greatly, with a mean Jadad
score of 2.7 (range, 1 to 5). Quality was greatest for studies
of prophylactic antibiotics where investigator and subject
blinding were possible (Jadad mean, 3.1 [range, 2 to 5];
antibiotics vs placebo).Reporting of allocation concealment was poor, with 22
studies failing to give a detailed description of randomiza-
tion methods. Adequate methods of concealment were
described in 11 of the 35 studies, and unconcealed ran-
domization methods were used in two studies.4,36
Prophylactic antibiotics versus placebo. Intravenous
cefazolin was compared with placebo in three double-blind
studies. Two of these included patients undergoing aortic
and lower limb reconstructions using both prosthetic and
vein grafts,3,8 and one study included only patients under-
going vein grafting in the group randomized to placebo.11
Intravenous cefuroxime in two dose regimens was com-
pared with placebo in a single double-blinded study of
lower limb prosthetic and vein bypasses,6 and intravenous
vancomycin was compared with placebo in a single un-
blinded study of prosthetic lower limb and aortic grafts.7
Two unblinded studies randomized patients to intrave-
nous cephradine or placebo4,10 for lower limb arterial
surgery. One of these studies10 also included varicose vein
operations, and there were two further randomization arms
of topical cephradine wound instillation either alone or
combined with intravenous cephradine. Results after arte-
rial reconstruction could only be extracted for the sub-
group of patients who received intravenous cephradine
alone or placebo and who underwent arterial reconstruc-
tion with a prosthetic graft.
One unblinded study randomized patients undergoing
procedures with prosthetic grafts to intravenous dicloxacil-
lin or placebo.5 A further double-blind study of patients
undergoing aortic or lower limb reconstruction compared
intravenous methicillin plus netilmicin with placebo.12 To-
bramycin plus lincomycin were compared with placebo in a
single study of prosthetic reconstructions.9
Patients with pre-existing infection, wet gangrene, or
who had received antibiotic therapy before surgery were
excluded in six studies of antibiotic vs placebo.6-8,10-12
Wound infection rates were recorded in all 10 studies, and
early graft infection in all but two.4,11
Studies of systemic antibiotics vs placebo showed a
homogeneous pattern demonstrating a consistent benefit
in reduction of wound infection in 1297 patients (RR fixed,
0.25; 95% CI, 0.17 to 0.38; P  .00001; Fig 1). Although
no single study demonstrated a statistically significant re-
duction in early graft infection with prophylactic systemic
antibiotics, the results of included studies appeared homo-
geneous, and in a fixed-effect model, a reduction in early
graft infection was evident on meta-analysis (RR fixed,
0.31; 95% CI, 0.11 to 0.85; P  .02; Fig 2). Late graft
infections were not identified in any study.
Four studies included patients undergoing aortic and
lower limb surgery. One of these studies did not document
the rates of infection for different surgical procedures.3 The
remaining three trials reported higher rates of infec-
tion7,8,12 in aortic grafting compared with lower limb
reconstruction. The RR of wound infection with prophy-
lactic antibiotics was similar at 0.20 (95% CI, 0.08 to 0.48)
for aortic and at 0.20 (95% CI, 0.06 to 0.69) for lower limb
reconstructions.
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thetic and vein grafts. Two reported differential infection
rates.3,10 The RR was 0.51 (95% CI, 0.24 to 1.11) for
wound infection with prosthetic grafts and 0.13 (95% CI,
0.04,0.41) for nonprosthetic grafts.
Short-duration versus long-duration prophylac-
tic antibiotics. The three identified studies in which
participants were randomized to prophylactic antibiotics
for  24 hours and  24 hours used different antibiotics
and regimens. One study in lower limb reconstructions
compared a 24-hour regimen of co-amoxiclav with a
5-day regimen; wound assessment was blinded.14 A fur-
ther unblinded study randomized all patients undergo-
ing open arterial surgery to intraoperative ticarcillin/
clavulanate alone and intraoperative plus continued
ticarcillin/clavulanate until all catheters were removed,
but  5 days.13 The third study randomized participants
to 24 hours of intravenous cefuroxime, 3 days of cefu-
roxime, or placebo. This double-blind study included
only patients undergoing lower limb reconstruction and
was the only study to exclude patients with pre-existing
cellulitis, wet gangrene, or recent antibiotic therapy.6
Continuing prophylactic antibiotics for  24 hours did
not appear to confer any additional benefit in reducing
wound infection compared with a 24-hour regimen (RR
fixed, 1.28; 95% CI, 0.82 to 1.98; Fig 3).
One study of a single dose of intravenous benzylpeni-
Fig 1. Review of studies comparing the effect of antibiot
reconstruction. RR  Relative risk; CI  confidence in
Fig 2. Review of studies comparing the effect of an
reconstruction. RR  Relative risk; CI  confidence incillin vs a 24-hour regimen was identified.35 This double-blinded study of general surgical patients included a vascu-
lar subgroup of 169 patients undergoing emergency or
elective surgery through a midline abdominal incision.
Wound infection rates were similar in both groups.
Randomized controlled trials of different antibiot-
ics or dose regimens. Four studies of intravenous cefazolin
randomized patients to receive cefazolin or cefaman-
dole,27,30 cefuroxime,26 teicoplanin,31 or vancomycin.30
The prophylactic regimen varied from single 2-gram intra-
venous dose,31 to a 48-hour regimen of either 1 gram every
6 hours,30 or a 2-gram initial dose and subsequently 1 gram
every 6 hours.26,27 One study compared a 48-hour regimen
of 1 gram of cefazolin with a similar regimen of 2 grams of
cefazolin.11
Two studies randomized patients to intravenous cefu-
roxime, either as a single 1.5-gram dose compared with a
single 2-gram dose of cephradine,24 or a 24-hour regimen
compared with 24 hours of oral ciprofloxacin.32
Other randomized studies comparing antibiotics in-
cluded single-dose 400-mg intravenous teicoplanin vs 24
hours of intravenous cephradine plus metronidazole,28 2.2
grams of intravenous co-amoxiclav at induction and 4
hours vs 2 grams of cefoxitin at induction and 4 hours,25
and 0.75 grams cefamandole at induction, 4, and 10 hours
vs 3 grams/200 mg ticarcillin plus clavulanic acid at induc-
tion, 4, and 10 hours.29
There was no evidence of a significantly greater reduc-
placebo on the outcome of wound infection after arterial
.
tics vs placebo on early graft infection after arterial
.ics vstibiotion in wound infection with comparable regimens of first-
sonfid
onfid
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lin/-lactamase inhibitor, aminoglycosides, or the
glycopeptides vancomycin or teicoplanin.
Rifampicin-bonded grafts. The results of three large
studies of rifampicin bonding are reported in four arti-
cles.15-18 All trials used an identical method of rifampicin
bonding, with soaking of a gelatin-coated Dacron graft in 1
mg/mL rifampicin for 15 minutes before insertion. The
Joint Vascular Research Group trial15,18 included only
patients undergoing extra-anatomic grafts (axillofemoral,
femorofemoral and iliofemoral crossover grafts), whereas
the Italian study16 included patients undergoing aorto-
monofemoral, bifemoral, or iliofemoral grafts. Only pa-
tients with rifampicin allergy were excluded from either
study, and both studies reported results up to 2 years.
All patients in the Joint Vascular Research Group study
received three doses of an intravenous antibiotic as part of a
local protocol,15 and 99% in the Italian study received
intravenous cephalosporin.16 The European study in-
Fig 3. Review of studies comparing effect of short-cou
after arterial reconstruction. RR  Relative risk; CI  c
Fig 4. Review of studies comparing the effect of rifampic
after arterial reconstruction. RR  Relative risk; CI  c
Fig 5. Review of studies comparing the effect of rifamp
arterial reconstruction. RR  Relative risk; CI  confidcluded patients undergoing aortofemoral grafts. Thisstudy’s wound and early graft infection results at 1 month
were reported in a review article.17
The three multicenter studies of rifampicin bonding to
gelatin-coated Dacron grafts reported early graft infection
outcomes in 3379 patients. Two of these studies (857
patients) reported graft infection outcomes to 2 years.
There was no evidence from these studies of a reduction in
graft infection at 1 month (RR fixed, 0.63; 95% CI, 0.27 to
1.49; Fig 4) or 2 years (RR fixed, 1.05; 95% CI, 0.46 to
2.40; Fig 5).
Suction wound drainage. Two randomized studies of
suction groin wound drainage were identified. One study
randomized a single groin wound in patients undergoing
arterial surgery through a longitudinal groin incision to
suction drainage or no drainage.19 Identical dressings were
applied after removal of the drains at 48 hours. Wound
assessment thereafter was by a blinded assessor. The other
tudy20 randomized right-side or left-side drainage in pa-
tibiotics vs long-course antibiotics on wound infection
ence interval.
aked graft vs control on early graft infection (1month)
ence interval.
oaked graft vs control on graft infection at 2 years after
interval.rse anin-soicin-stients undergoing arterial surgery with bilateral groin inci-
terval
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geon, and wound assessment was unblinded.
There was no evidence that suction drainage of groin
wounds conferred a beneficial or detrimental effect on rates
of wound infection (RR fixed, 0.96; 95% CI, 0.50 to 1.86;
Fig 6). The effect of suction wound drainage on early or late
graft infection has not been studied.
Preoperative skin antisepsis. Preoperative antisepsis reg-
imens using chlorhexidine were compared with placebo in
two studies,21,22 and povidone iodine was compared with
control in one further study.23 The chlorhexidine regimen
involved painting all over with undiluted chlorhexidine and
rinsing in the bath twice preoperatively21 or three preopera-
tive showers with 4% chlorhexidine.22 The povidone iodine
regimen consisted of twice-daily painting of skin from nipple
to knees for 2 preoperative days.23 A preoperative bathing or
shower regimen with antiseptic agents did not confer any
benefit in reducing wound infection (RR, 0.97; 95% CI, 0.70
to 1.36; Fig 7). The effect on subsequent early or late graft
infection has not been studied.
Other studies.Two studies of in situ lower limb bypass
graft techniques reported wound infection outcomes. Both
trials used methods to reduce the need for exposure of the
entire vein bypass through a long incision in the leg. One
study randomized patients to coil embolization of vein side
branches or to a standard in situ technique.37 The other
study compared angioscopically assisted valve lysis and vein
branch identification that allowed minimal incisions with a
standard technique that used an incision along the full
Fig 6. Review of studies comparing the effect of va
reconstruction. RR  Relative risk; CI  confidence in
Fig 7. Review of studies comparing the effect of preop
reconstruction. RR  Relative risk; CI  confidence inlength of the leg.36Wound infection outcomes weremeasured in two stud-
ies of in situ lower limb bypass surgery in which techniques
were used to minimize length of skin incisions. The out-
comes of these two small studies differed: the trial of
angioscopically assisted vein branch identification reported
no effect on wound infection (RR fixed, 0.84; 95%CI, 0.06
to 12.86), and the trial of coil embolization of vein
branches reported a significant reduction of wound infec-
tion complications (RR fixed, 0.47; 95% CI, 0.31 to 0.73).
Wound observers in this latter trial were unblinded; there-
fore, the findings of this single study should be treated with
some caution.
Single studies of intraoperative glove change33 and
methods of wound closure34 failed to show any reduction
in superficial wound infection.
DISCUSSION
Graft infection remains a serious limb-threatening and
often life-threatening complication reported after 1% to 6%
of all arterial reconstructions. Most deep wound and graft
infections appear to be caused by implantation of bacteria
from the patient’s skin at the time of surgery or by direct
spread during the early postoperative period.51-53 Re-
cently, resistant bacteria such as methicillin-resistant Staph-
ylococcus aureus (MRSA) have increased in prevalence and
now appear to account for most of the deep wound infec-
tions in the United Kingdom and Ireland.54 Measures to
minimize the risk of infection are therefore essential in
arterial reconstruction. Research on prevention of infection
drain vs no drain on wound infection after arterial
.
e antisepsis vs control on wound infection after arterial
.cuumerativ
tervalhas mainly concentrated on antibiotic prophylaxis, with 22
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antibiotics. Many other interventions aimed at minimizing
operative infection have been poorly studied.
In this review, the nonantibiotic interventions lacked
evidence of effectiveness. The numbers of patients re-
cruited to these studies were small, however, and this is
reflected by the broader confidence intervals on meta-
analyses.
Preoperative measures. Patients undergoing arterial
reconstruction often have pre-existing risk factors for
wound complications. Poor diabetes control, dependent
limb edema, and poor nutrition may increase the risk of a
significant wound and graft infection postoperatively. It
seems sensible that these factors should be optimized be-
fore elective surgery, although we were unable to identify
any trials of specific interventions for these risk factors.
Increased bacterial colonization, particularly in groin
creases, and colonization with resistant bacteria such as
MRSA may also increase the risks of infection. This review
found no evidence of any additional benefit with a more
aggressive bathing or showering regimen that used antisep-
tics compared with simple bathing with nonmedicated
soap. No trials of the effect of MRSA decolonization pre-
operatively were identified, despite evidence of efficacy in a
systematic review in other specialties.55
Operative and postoperative measures. This review
demonstrated that prophylactic treatment with systemic
antibiotics commenced immediately preoperatively re-
duced the risk of wound infection and almost certainly early
graft infection by between two thirds and three quarters.
Broad-spectrum cephalosporins, penicillin/-lactamase in-
hibitors, or aminoglycosides would appear to confer similar
benefits. A high local prevalence of antibiotic-resistant or-
ganisms or pre-existing colonization with MRSA may ne-
cessitate use of vancomycin or teicoplanin. A 24-hour
regimen of antibiotics appears as effective as prophylaxis
continued 24 hours.
Basic theatre asepsis procedures are a prerequisite for
arterial surgery. Evidence of the benefit of other theatre
interventions is, however, very sparse. In particular, no
RCTs of choice of skin antisepsis before surgery or use of
bio-occlusive drapes were identified, and no trials of ultra-
clean operating theater airflow for vascular surgery have
been reported, although this is established practice for the
insertion of orthopedic implants. Intraoperative glove
change before handling prosthetic grafts did not seem to
reduce contamination of graft material, and no effect on
wound infection was detectable in the single small study.33
The use of rifampicin impregnation of prosthetic graft
material appeared to have no benefit in preventing early or
late graft infection. It has been speculated this may have
been due to the low concentration of rifampicin used (1
mg/mL), and there remains scope for further research into
the use of a vascular graft as a vehicle for drug delivery,
particularly now that silver-coated grafts are available.56
The research analyzed here extended for almost 30
years. In the last decade, MRSA has changed the face of
vascular infection. It is perhaps the most virulent organismcurrently challenging the vascular patient: aortic graft in-
fection is almost universally fatal, and infrainguinal infec-
tion usually results in amputation. Few trials concerning
MRSA infection exist in vascular surgery. The only investi-
gations so far concern isolation policies that appear effective
in open trials.57,58 This is an urgent problem in need of
research focus.59
CONCLUSION
In addition to basic skin cleanliness and operating
theater antisepsis procedures, patients undergoing arterial
reconstruction should receive systemic antibacterial pro-
phylaxis using an antibiotic with activity against staphylo-
coccal and gram-negative bacteria. This review has exposed
the limited nature of research in this area, despite the
devastating effects of vascular graft infection. Large multi-
center trials are needed, particularly with respect to the
effects of bio-occlusive drapes and ultra-clean operating
theater airflow.
We would like to thank the Cochrane Peripheral Vas-
cular Diseases Group for Peripheral Vascular Diseases Re-
view Group for providing us with information from the
Group’s specialized register. This article is based on a
Cochrane Review; the full report can be viewed at www.
cochrane.org/reviews/en/ab003073.html. Accessed Oct
17, 2006.
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